People: Insulet Corp (PODD.O)

Summary

Name	Age	Since	Current Position
Duane DeSisto	58	2003	President, Chief Executive Officer, Director
Brian Roberts	42	2009	Chief Financial Officer
Charles Liamos	53	2011	Chief Operating Officer, Director
R. Anthony Diehl	44	2012	General Counsel, Secretary
Peter Devlin	45	2009	Chief Commercial Officer
Sally Crawford	59		Lead Independent Director
W. Mark Lortz	61	2012	Director
John Fallon	65	2012	Independent Director
Daniel Levangie	62	2011	Independent Director
Steven Sobieski	56	2006	Independent Director
Regina Sommer	55	2008	Independent Director
Joseph Zakrzewski	50	2008	Independent Director

» Insider Trading

Biographies

Name	Description
Duane DeSisto	Mr. Duane M. DeSisto is President, Chief Executive Officer, Director of Insulet Corporation. He has served as the company's President, Chief Executive Officer and a director since 2003. From 2002 to 2003, he served as the company's President, Chief Financial Officer and acting Chief Executive Officer. From 2001 to 2002, he served as Chief Financial Officer and Treasurer. From 1999 to 2001, Mr. DeSisto served in various positions at PaperExchange.com, Inc., a business solutions provider for the pulp and paper industry, including as president, chief executive officer and chief financial officer. From 1995 to 1999, Mr. DeSisto served as the chief financial officer of FGX International Holdings Limited (formerly AAI-Foster Grant, Inc.), an accessories wholesaler, where he had overall responsibility for the accounting, information technology and human resource departments. From 1986 to 1995, Mr. DeSisto served as the chief financial officer of ZOLL Medical Corporation, a medical device company specializing in noninvasive resuscitation devices and related software solutions. Mr. DeSisto earned a Bachelor of Science from Providence College and a Master of Business Administration from Bryant College.
Brian Roberts	Mr. Brian K. Roberts is Chief Financial Officer of Insulet Corporation, since March 5, 2009. From 2007 to March 2009, Mr. Roberts served as the chief financial officer of Jingle Networks, Inc., the operator of an ad-supported directory assistance service. From 2005 to 2007, Mr. Roberts served as the chief financial officer of Digitas Inc., a digital marketing and media services firm. Mr. Roberts also served as senior vice president, chief accounting officer and corporate controller of Digitas from 2001 to 2005. Prior to 2001, Mr. Roberts held senior finance positions at Idiom Technologies, Inc., the Monitor Group and Ernst & Young LLP. Mr. Roberts earned a Bachelor of Science in accounting and finance from Boston College and is a Certified Public Accountant.
Charles Liamos	Mr. Charles T. Liamos is Chief Operating Officer, Director of Insulet Corporation. He has served as the company's Chief Operating Officer since January 2011 and has served on the company's Board of Directors since 2005. Mr. Liamos has been associated with MedVenture Associates since 2006, first as the executive-in-residence and then as a partner in MedVenture Associates Management V Co., LLC, which is the general partner of MedVenture Associates V, L.P. and MedVenture Affiliates V, L.P. On behalf of MedVenture Associates, he serves on the board of directors of several privately-held companies. From 2005 to 2006, Mr. Liamos served as the president and chief executive officer of FoviOptics, Inc., a medical device company that focuses on blood glucose monitoring. Before joining FoviOptics, Mr. Liamos served as the chief operating officer and chief financial officer of TheraSense, Inc. from 2001 to 2004, as its vice president and chief financial officer from 1999 to 2001, and as its director of finance and operations from 1998 to 1999. When Abbott Laboratories, Inc. acquired TheraSense in 2004, Mr. Liamos was named group vice president of business operations for Abbott Diabetes Care and served on the committee that integrated TheraSense into its new parent company. From 1995 to 1998, Mr. Liamos was the director of worldwide sourcing at LifeScan, Inc., a division of Johnson & Johnson. Mr. Liamos earned a Bachelor of Science from the University of Vermont and is a graduate of the General Electric Financial Management Program.
R. Anthony Diehl	Mr. R. Anthony Diehl is General Counsel, Secretary of Insulet Corporation. From 2001 to 2003, he was Of Counsel at Bourque & Associates, P.A. where his practice covered all areas of intellectual property law, including patent, trademark and copyright prosecution, counseling and litigation. Mr. Diehl earned a Bachelor of Arts from Cornell University and a Juris Doctor from Villanova University School of Law.
Peter Devlin	Mr. Peter Devlin is Chief Commercial Officer of Insulet Corporation, since August 17, 2009. From 1998 to 2009, Mr. Devlin served in various positions with Abbott Laboratories, Inc., most recently as divisional vice president of global strategic marketing. From 1996 to 1998, he served as marketing manager of i-STAT Corporation, a point-of-care blood analysis systems company which was acquired by Abbott Laboratories. Mr. Devlin also held a variety of product management and engineering roles with C.R. Bard, Inc. from 1988 to 1996. Mr. Devlin earned a Bachelor of Science in mechanical engineering from the University of Massachusetts.
Sally Crawford	Ms. Sally W. Crawford is Lead Independent Director of Insulet Corporation. She has served on the company's Board of Directors since 2008. Ms. Crawford served as chief operating officer of Healthsource, Inc., a publicly-held managed care organization from its founding in 1985 until 1997. During her tenure at Healthsource, she led the development of its operating systems and marketing strategies and supported strategic alliances with physicians, hospitals, insurers and other healthcare companies. Since 1997, Ms. Crawford has been a healthcare consultant. Ms. Crawford serves on the boards of directors of Hologic, Inc., Exact Sciences Corporation, Zalicus Inc., Universal American Corp. and Prolacta Bioscience Inc. She also served on the board of directors of Chittenden Corporation from 1998 until 2008. Ms. Crawford earned a Bachelor of Arts from Smith College and a Master of Science from Boston University.
W. Mark Lortz	Mr. W. Mark Lortz is Director of Insulet Corp., since July 25, 2012. Mr. Lortz brings experience in the diabetes industry, having served as the Chairman, President and Chief Executive Officer of blood glucose monitoring manufacturer TheraSense, Inc. from 1997 to 2004, when it was acquired by Abbott Laboratories. He led TheraSense from venture stage, to its IPO, launching the company’s Freestyle brand blood glucose technology in over 40 countries. Previously, Mr. Lortz served at LifeScan, Inc., a Johnson & Johnson company specializing in diabetes management technology, where his roles included Group Vice President of Worldwide Operations and International Franchise Development. Among his responsibilities at LifeScan, Mr. Lortz directed quality assurance, regulatory affairs and new product planning. Previously, Mr. Lortz spent two decades at the General Electric Company in various engineering, production and operational roles. Mr. Lortz was a member of the board at the Diabetic Youth Foundation from 1996 to 2002. He holds a Bachelor of Science degree from Iowa State University and a Master of Business Administration degree from Xavier University.
John Fallon	Dr. John A. Fallon is an Independent Director of Insulet Corp., since 24 October 2012. Since 2004, Dr. Fallon has served as the Chief Physician Executive and Senior Vice President at Blue Cross Blue Shield of Massachusetts (BCBSMA), the health plan in Massachusetts with approximately 3 million members. At BCBSMA he is responsible for health plan initiatives focusing on policy, quality, affordability, innovative reimbursement and care management models. From 2000 to 2004, Dr. Fallon served as Chief Executive Officer for Clinical Affairs at the State University of New York Downstate Medical Center. Previously, Dr. Fallon was with Partners Healthcare System (PHS), a non-profit community healthcare system founded by The Massachusetts General Hospital and The Brigham and Women’s Hospital. He served as a Trustee for PHS’s Physician Network and as its Chairman from 1998 to 2000. Dr. Fallon had an internal medicine practice in Salem, Massachusetts for over two decades Dr. Fallon serves on numerous boards, including the Temple University School of Medicine Board of Advisors and as Chairman of NEHI, formerly the New England Health Institute. Dr. Fallon received a Bachelor’s degree from the College of the Holy Cross, his M.D. from Tufts University School of Medicine and a Master’s degree in Business Administration from the University of South Florida.
Daniel Levangie	Mr. Daniel J. Levangie is an Independent Director of Insulet Corporation, since October 19, 2011. Mr. Levangie has been the chief executive officer and director of Dune Medical Devices, Inc., a private medical device company, since October 2011. He is also a principal and managing partner at Constitution Medical Investors, a private equity firm focused on the healthcare sector, a role he had held since February 2008. Mr. Levangie formerly served as president and chief executive officer of Keystone Dental Inc. from 2009 until 2011. From 1992 to 2007, Mr. Levangie held various executive management and leadership roles at Cytyc Corporation, most recently as president of Cytyc Surgical, until the company was acquired by Hologic, Inc. From 1975 to 1992, Mr. Levangie held various sales and marketing management positions at Abbott Laboratories, Inc. He currently serves as chairman of the board of directors of Keystone Dental, and as director of Liposcience, Inc. and Exact Sciences Corporation. Mr. Levangie also served as a member of the board of directors of ev3, Inc. from 2007 to 2011 and as chairman of the board of directors of ev3 from 2008 to 2011. Mr. Levangie received his Bachelor of Science in Pharmacy from Northeastern University.
Steven Sobieski	Mr. Steven T. Sobieski is an Independent Director of Insulet Corporation, since December 2006. Mr. Sobieski currently serves as senior vice president and chief financial officer of Roka Bioscience, Inc., a position he has held since September 2009. Prior to joining Roka Bioscience, he served as chief financial officer and vice president of finance and administration of LifeCell Corporation, a public company focused on developing and marketing reconstructive surgical products from 2000 to 2009. Mr. Sobieski served as vice president of finance and in other positions at Osteotech, Inc., a public company focused on orthopedic products, from 1991 to 2000. From 1981 through 1991, he was with Coopers & Lybrand, a public accounting firm. Mr. Sobieski earned a Bachelor of Science in business administration from Monmouth University and a Master of Business Administration from Rutgers University. He is a Certified Public Accountant.
Regina Sommer	Ms. Regina O. Sommer is an Independent Director of Insulet Corporation, since May 8, 2008. From 2002 through 2005, she served as the vice president and chief financial officer of Netegrity, Inc., which was acquired by Computer Associates Inc. in November 2004. From 1999 to 2001, she served as the vice president and chief financial officer of Revenio, Inc. From 1995 to 1999, she served as senior vice president and chief financial officer of Open Market, Inc., and from 1989 to 1994, she served as the vice president of finance at The Olsten Corporation. She also worked at PricewaterhouseCoopers LLP from 1980 to 1989. Ms. Sommer serves on the boards of directors of Soundbite Communications, Inc. and Wright Express Corporation. Ms. Sommer also served on the board of directors of ING Direct from 2008 to February 2012. Ms. Sommer earned a Bachelor of Arts from the College of the Holy Cross.
Joseph Zakrzewski	Mr. Joseph S. Zakrzewski is an Independent Director of Insulet Corporation. He has served on the company's Board of Directors since 2008. Mr. Zakrzewski currently serves as chairman and chief executive officer of Amarin Corporation, a publicly-held company focused on development and commercialization of cardiovascular drugs based on Omega 3s. From 2007 to 2010, he served as chairman of the board of directors, president and chief executive officer of Xcellerex Incorporated, a privately-held company focusing on commercializing its proprietary, next-generation manufacturing technology for biotherapeutics and vaccines. From 2005 to 2007, Mr. Zakrzewski served as the chief operating officer of Reliant Pharmaceuticals, Inc. From 1988 to 2005, Mr. Zakrzewski served in a variety of positions at Eli Lilly and Company, including as vice president, corporate business development from 2003 to 2005. He serves on the boards of directors of Acceleron Pharma, Inc., Amarin Corporation, and Azelon Pharmaceuticals, Inc. Mr. Zakrzewski earned a Bachelor of Science in chemical engineering and a Masters in biochemical engineering from Drexel University, as well as a Master of Business Administration from Indiana University.

Basic Compensation

Name	Fiscal Year Total
Duane DeSisto	2,851,290
Brian Roberts	1,239,220
Charles Liamos	1,490,700
R. Anthony Diehl	991,451
Peter Devlin	1,093,870
Sally Crawford	--
W. Mark Lortz	--
John Fallon	--
Daniel Levangie	--
Steven Sobieski	--
Regina Sommer	--
Joseph Zakrzewski	--

As Of 30 Dec 2012

Options Compensation

Name	Options	Value
Duane DeSisto	200,000	3,293,110
Brian Roberts	110,000	1,640,800
Charles Liamos	0	0
R. Anthony Diehl	35,667	528,612
Peter Devlin	60,000	642,300
Sally Crawford	0	0
W. Mark Lortz	0	0
John Fallon	0	0
Daniel Levangie	0	0
Steven Sobieski	0	0
Regina Sommer	0	0
Joseph Zakrzewski	0	0

Insider Trading

Name	Shares Traded	Price
DESISTO DUANE M	20,000	$24.86
DESISTO DUANE M	20,000	$3.60
DEVLIN PETER	2,346	$26.00
LIAMOS CHARLES T	2,932	$26.00
DESISTO DUANE M	20,000	$3.60
DIEHL R ANTHONY	1,633	$26.00
ROBERTS BRIAN K	2,041	$26.00
DESISTO DUANE M	8,269	$26.00
DESISTO DUANE M	20,000	$25.68
DIEHL R ANTHONY	3,643	$23.40
DIEHL R ANTHONY	12,500	$0.00
DESISTO DUANE M	20,000	$22.06
DESISTO DUANE M	60,000	$0.00
ROBERTS BRIAN K	5,172	$23.40
DEVLIN PETER	30,000	$8.30
DESISTO DUANE M	20,000	$3.60
LIAMOS CHARLES T	30,000	$0.00
DEVLIN PETER	16,800	$0.00
DEVLIN PETER	5,688	$23.40
DEVLIN PETER	30,000	$22.11
ROBERTS BRIAN K	30,000	$0.00
DESISTO DUANE M	11,374	$23.40
LIAMOS CHARLES T	11,917	$21.22
ROBERTS BRIAN K	1,566	$21.22
DIEHL R ANTHONY	25,836	$21.58

» Full list on Insider Trading

People: Insulet Corp (PODD.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: